Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Oct 21, 2022 11:42am
186 Views
Post# 35039040

RE:RE:Lol

RE:RE:LolHey-Hey Yellowknifer !!!
Nice to hear from you.
Exactly - there are no buyers (haven't been) - and those that need cash are being squeezed hard.

We really need the last news release to evlove into some real plans going forward - some real dosing/regimen numbers that people can understand - for acute and chronic alike.

Then we need a plan to go after new shareholders - untainted.
That will drive old shareholders back - fear of missing out kinda thing.

Hoping it's just so misunderstood as the various head-to-head science work this summer has likely been huge.  Also - not sure if that head-to-head is even done yet.  352 is in question (can 346 do it now?) and not sure if IBD likely benefits from a similar change - or maybe already there.  Tough to say - not enough information.

Need details to follow !

-------------------------



Yellowknifer69 wrote: Hello and good morning ATE Longs:

While the stock is definitely heading in the wrong directions,  it obvious that ATE is following broader market trends.  Nobody is spending money at the moment.

But then you have losers, like Stutters, that can do nothing except make fun of others.  it is sad to have to put him on the IGGY list but just so sick of listening to his drivel.

Take ccccare sttttutters - I miss you already!

Yellowknifer


<< Previous
Bullboard Posts
Next >>